Landfar(SZ:000504) Xin Lang Cai Jing·2026-01-20 03:53Group 1 - The core point of the article is that *ST Bio (SZ000504) experienced a trading halt with a price increase of 5.04% to 9.38 yuan, driven by significant asset restructuring, government subsidies, and improved performance [1] Group 2 - The company is advancing a major asset restructuring by acquiring 51% of Huize Pharmaceutical to expand its biopharmaceutical business and enhance competitiveness, although the project is still in the planning stage and carries uncertainties [1] - The company received a government subsidy of 4.8 million yuan, which directly increased its current profits by 24.19% of the latest net profit [1] - The third-quarter report indicates a 162% year-on-year increase in net profit attributable to shareholders, with operational improvements noted [1] - The company has engaged in hedging activities to mitigate risks from lithium carbonate price fluctuations, stabilizing operational costs [1] - The transfer of 23.41 million yuan in accounts receivable has improved cash flow, and the company has been approved for a 300 million yuan comprehensive credit line to support business development [1] - The biopharmaceutical and energy-saving environmental protection sectors are currently hot areas in the industry, with related stocks showing good performance, creating a sectoral linkage effect [1] - Although specific technical indicators were not obtained, the influx of funds attracted by the aforementioned positive factors likely contributed to the stock price surge [1] - Data from Dongfang Caifu indicates that the stock experienced a net inflow of main funds on that day [1]